TDP43-Binding Compounds for Neurodegenerative Disorder Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic and therapeutic options for TDP43-mediated disorders, such as ALS and FTD, lack reliable and sensitive methods for imaging and treatment, as TDP43 aggregates are difficult to detect and target effectively.
Innovation Solution
Development of compounds that selectively bind to TDP43 aggregates, allowing for diagnostic imaging and therapeutic intervention by using PET/SPECT/OPTICAL probes and potentially delivering therapeutic agents across the blood-brain barrier.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods are used for TDP43-mediated disorders, then general disease detection is possible, but sensitive and specific detection of TDP43 aggregates is not achieved
Solution Approach 1:
The patent modifies molecular parameters by designing compounds with specific chemical structures (formula I, II, or III) that contain TDP43-binding moieties. These structural parameter changes enable the compounds to selectively bind to TDP43 aggregates with high affinity, achieving sensitive and specific detection without requiring complex imaging equipment beyond standard PET/SPECT/optical imaging capabilities.
2Reliability
If TDP43 aggregates are targeted for therapy, then treatment of ALS and FTD is improved, but effective delivery across the blood-brain barrier becomes more difficult
Solution Approach 1:
The patent designs compounds that serve multiple functions simultaneously: they act as imaging agents for detecting TDP43 aggregates and as therapeutic agents for treating the underlying pathology. This multi-functionality is achieved by incorporating both the TDP43-binding moiety and therapeutic functional groups into a single molecular structure, eliminating the need for separate delivery systems for diagnostics and therapeutics.
Solution Approach 2:
The compounds described in the patent serve as intermediaries that can cross the blood-brain barrier and deliver therapeutic effect to TDP43 aggregates in the brain. The molecular structures are designed to have appropriate lipophilicity and size to traverse the blood-brain barrier while maintaining high affinity for TDP43 aggregates, thus acting as effective mediators between systemic administration and central nervous system target.
3Loss of time
If early diagnosis of TDP43-mediated disorders is achieved, then patient outcomes are improved, but reliable detection methods are currently unavailable
Solution Approach 1:
The patent enables preliminary detection of TDP43 aggregates before significant neuronal loss and clinical symptom manifestation occur. The compounds can bind to early-stage TDP43 aggregates with high specificity, allowing for pre-symptomatic or early-stage diagnosis. This preliminary action of detection enables earlier intervention and treatment initiation, improving patient outcomes while maintaining high detection reliability through specific molecular binding.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds provide a sensitive and specific means for detecting TDP43 aggregates, enabling effective diagnosis and treatment of TDP43-mediated disorders, including ALS and FTD, while also facilitating the delivery of therapeutic agents to the brain.
Implementation Method 1
The compounds disclosed bind TDP43 aggregates and may be used to diagnose and treat amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD)
Data Source
AI summary
Provided herein are compounds for the imaging and treatment of TDP43-mediated disorders. The compounds disclosed bind TDP43 aggregates and may be used to diagnose and treat amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).